Hwang Y-C, Woo Oh S, Park S-W, Park C-Y
Division of Endocrinology and Metabolism, Department of Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea.
Department of Family Medicine, Center for Obesity, Nutrition and Metabolism, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang, Republic of Korea.
Int J Obes (Lond). 2014 Sep;38(9):1207-12. doi: 10.1038/ijo.2013.242. Epub 2013 Dec 20.
C1q/TNF-Related Protein (CTRP) family members are novel adipokines that have anti-inflammatory, immunomodulatory, glucose-regulating and vascular effects. However, the metabolic effects of CTRP9 remain unclear in humans.
The aims of this study were to investigate whether serum CTRP9 concentrations are associated with glucose tolerance, metabolic parameters and abdominal fat accumulation. In addition, the authors investigated whether the aforementioned effects of CTRP9 are independent of serum adiponectin levels.
A total of 221 subjects (140 men and 81 women), 25-72 years of age (mean age 46.0 years), were randomly selected from two different study populations. The normal glucose tolerance group (n=120) was selected from one study population and the prediabetes/type 2 diabetes group (n=101) was selected from the other study population. Serum CTRP9, total adiponectin concentrations and abdominal fat via computed tomography scan were measured in all subjects.
Subjects in the lower serum CTRP9 tertile were older, had metabolically unhealthy profiles and had lower serum total adiponectin levels when compared with subjects in the middle or upper serum CTRP9 tertiles. In addition, serum CTRP9 concentration were inversely correlated with age, blood pressure, fasting glucose, homeostasis model assessment for insulin resistance, total cholesterol, triglyceride and low-density lipoprotein cholesterol levels (all P<0.01) and positively correlated with serum total adiponectin levels (P=0.03). In terms of abdominal fat accumulation, serum CTRP9 concentrations were inversely correlated with visceral fat amount (P<0.01), but no correlation was observed with subcutaneous fat amount. Finally, serum CTRP9 was inversely associated with the presence of metabolic syndrome, independent of age, sex, body mass index, smoking status, total cholesterol, visceral fat and serum total adiponectin concentrations (odds ratio per 1 s.d. 0.47; 95% confidence interval 0.32-0.70; P<0.01).
Serum CTRP9 concentrations were positively associated with favorable glucose or metabolic phenotypes and absence of metabolic syndrome, independent of serum total adiponectin concentrations.
C1q/TNF相关蛋白(CTRP)家族成员是一类新型脂肪因子,具有抗炎、免疫调节、血糖调节和血管相关作用。然而,CTRP9在人体中的代谢作用仍不清楚。
本研究旨在探讨血清CTRP9浓度是否与糖耐量、代谢参数及腹部脂肪堆积相关。此外,作者还研究了CTRP9的上述作用是否独立于血清脂联素水平。
从两个不同的研究人群中随机选取221名受试者(140名男性和81名女性),年龄在25 - 72岁之间(平均年龄46.0岁)。正常糖耐量组(n = 120)从一个研究人群中选取,糖尿病前期/2型糖尿病组(n = 101)从另一个研究人群中选取。对所有受试者测量血清CTRP9、总脂联素浓度,并通过计算机断层扫描测量腹部脂肪。
与血清CTRP9三分位数处于中、高组的受试者相比,血清CTRP9三分位数处于低组的受试者年龄更大,代谢状况不健康,血清总脂联素水平更低。此外,血清CTRP9浓度与年龄、血压、空腹血糖、胰岛素抵抗稳态模型评估、总胆固醇、甘油三酯和低密度脂蛋白胆固醇水平呈负相关(均P < 0.01),与血清总脂联素水平呈正相关(P = 0.03)。在腹部脂肪堆积方面,血清CTRP9浓度与内脏脂肪量呈负相关(P < 0.01),但与皮下脂肪量无相关性。最后,血清CTRP9与代谢综合征的存在呈负相关,独立于年龄、性别、体重指数、吸烟状况、总胆固醇、内脏脂肪和血清总脂联素浓度(每标准差的比值比为0.47;95%置信区间为0.32 - 0.70;P < 0.01)。
血清CTRP9浓度与良好的血糖或代谢表型以及无代谢综合征呈正相关,独立于血清总脂联素浓度。